Editing Prostate Cancer: Management of Locally Advanced Prostate Cancer (section)

====== European Organization for Research and Treatment of Cancer (EORTC) 22911 ======
* Initiated in 1992
* Population: 1005 men with pT3 prostate cancer and/or positive surgical margins
* Randomized to adjuvant RT vs. observation
* Results:
** Biochemical progression–free survival rate was improved by 21% at 5-years in the adjuvant radiation arm (74% adjuvant vs. 53% salvage arm)
** Clinical progression–free survival, defined as no evidence of clinical, sonographic, radiographic, or scintigraphic recurrence, was improved in the adjuvant radiation group compared to the salvage group, as was locoregional failure at 5 years, which was significantly lower in the adjuvant radiation group and 5.4% versus 15.4% in the salvage group.
** No difference in overall survival
** Bolla, Michel, et al. "Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)." The Lancet 380.9858 (2012): 2018-2027. <nowiki>https://www.ncbi.nlm.nih.gov/pubmed/23084481</nowiki> [Original publication 2005]
** Secondary analyses of EORTC 22911 support the role of immediate RT in the specific subset with positive surgical margin (Van der Kwast et al, 2007). The treatment benefit on biochemical-free survival of adjuvant RT was primarily seen in patients with positive surgical margins (HR 0.38, P < .0001), whereas no benefit was observed in those with negative margins independent of other risk factors.